Finding genetic differences that affect survival after blood and marrow transplant
Multi-ethnic high-throughput study to identify novel non-HLA genetic contributors to mortality after blood and marrow transplantation
This project looks for genetic differences beyond HLA that might explain why some people die within a year after an allogeneic blood and marrow transplant.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Roswell Park Cancer Institute Corp NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project ID | NIH-11131211 on NIH RePORTER |
What this research studies
From a patient's point of view, researchers are comparing DNA from donors and transplant recipients across multiple ancestries to find non-HLA genetic variants linked to survival after transplant. They will use whole-exome sequencing and large-scale genome scans (GWAS) combined with existing transplant datasets to search for both rare and common variants. The team will study donor-recipient genotype mismatches as well as genes previously flagged in European American patients, and expand analyses to under-studied populations. Ultimately they plan to build clinical-genomic risk models that could be used to guide donor choice and post-transplant care.
Who could benefit from this research
Good fit: People who have had or are planning an allogeneic (donor) blood or marrow transplant, especially those with HLA-matched unrelated donors and from diverse racial or ethnic backgrounds, are the most relevant candidates.
Not a fit: People receiving autologous transplants, those without an identifiable donor, or individuals whose donor/recipient DNA cannot be obtained are unlikely to benefit directly from this project.
Why it matters
Potential benefit: If successful, this work could lead to genetic tests or risk tools that help choose safer donors and personalize care to lower transplant-related deaths.
How similar studies have performed: Previous GWAS and exome-wide studies by this group found donor loci and rare variants tied to mortality in European American patients, but applying these approaches broadly across diverse populations is relatively new.
Where this research is happening
Buffalo, United States
- Roswell Park Cancer Institute Corp — Buffalo, United States (Active)
Researchers
- Principal investigator: Hahn, Theresa E — Roswell Park Cancer Institute Corp
- Study coordinator: Hahn, Theresa E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.